07:00 , Oct 5, 2015 |  BioCentury  |  Finance

Asceneuron's clinical path

Investors pulled the trigger on a CHF30 million ($30.7 million) A round for preclinical neurology play Asceneuron S.A. last week thanks to a combination of in vivoproof-of-concept data and advances in neurological imaging technologies that...
01:05 , Sep 30, 2015 |  BC Extra  |  Financial News

Asceneuron raises CHF30 million series A round

Neurology company Asceneuron S.A. (Lausanne, Switzerland) raised CHF30 million ($30.7 million) in a series A round led by new investor Sofinnova Partners. Also participating were new investors SR One; Kurma Partners; and Johnson & Johnson...
08:00 , Mar 2, 2015 |  BioCentury  |  Emerging Company Profile

The road to Tau

Asceneuron S.A. is working to treat neurodegeneration by preventing formation of neurofibrillary tangles in the hopes this mechanism will fare better in treating Alzheimer's disease than amyloid-targeted products. Neurofibrillary tangles arise when microtubule-associated protein...